

JC10 Rec'd PCT/PTO 17 OCT 2001

PA-9848 #8

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to the: Assistant Commissioner for Patents Washington, D.C. 20231.

Melissa Leck
Type or print name

Signature

October 15, 2001
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: P. Knox, et al.

Group Art Unit: 1641

Serial No.: 09/869,629

Examiner: To be assigned

Filing Date: September 21, 2001

Title: NMR Spectroscopic In Vitro Assay Using Hyperpolarization

RECEIVED
MAR 29 2002
TECH CENTER 1600/2900

REQUEST FOR A CORRECTED FILING RECEIPT

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, D.C. 20231

Sir:

Please furnish the undersigned with a corrected filing receipt for the above-identified application. The corrections required is as follows:


In the "Applicant(s)" section, please add the following missing Applicant:

Jan Henrik Ardenkjaer-Larsen, Malmo, SWEDEN

Enclosed is a marked up copy of the Filing Receipt having a mailing date of October 1, 2001. Additionally, enclosed is a copy of the Declaration as executed by the inventors, including the above referenced inventor, as filed with the U.S. Patent Office on September 21, 2001. Any questions can be referred to the undersigned.

Amersham Pharmacia Biotech, Inc.
P.O. Box 1327
800 Centennial Avenue
Piscataway, New Jersey 08855-1327
(732) 457-8071 (voice)
(732) 457-8463 (facsimile)

Respectfully submitted,


Stephen G. Ryan
Reg. No. 39,015



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/869,629	09/21/2001	1641	1152	PA-9848	2	29	1

CONFIRMATION NO. 5709

22840

AMERSHAM PHARMACIA BIOTECH INC
PATENT DEPARTMENT
P O BOX 1327
800 CENTENNIAL AVENUE
PISCATAWAY, NJ 088551327

RECEIVED
MAR 29 2002
TECH CENTER 1600/2900

FILING RECEIPT



OC000000006820655

Date Mailed: 10/01/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Peter Knox, Chalfont St. Giles, UNITED KINGDOM;
Neil Cook, Chepstow, UNITED KINGDOM;
Klaes Golman, Malmo, SWEDEN;
Haukur Johannesson, Malmo, SWEDEN;
Oksar Axelsson, Malmo, SWEDEN;
Jan Henrik Ardenkjaer-Larsen, Malmo, SWEDEN

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A 371 OF PCT/GB99/04410 12/23/1999


Foreign Applications

UNITED KINGDOM 9828852.5 12/30/1998
UNITED KINGDOM 9918096.0 08/02/1999

Projected Publication Date: Not Applicable, filed prior to November 29, 2000

Non-Publication Request: No

Early Publication Request: No



Title

Nmr spectroscopic in vitro assay using hyperpolarization

Preliminary Class

435

LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15 (b).